secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001104659-25-002863
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax reaffirms full year 2024 guidance; presents at J.P. Morgan conference
-----------------------------------------------------------------------------

- Reaffirmed full year 2024 financial guidance, no specific figures provided.
- Preliminary expectations for combined R&D and SG&A expenses for 2025 and 2026 mentioned without numbers.
- Presenting strategic updates at 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925002863/0001104659-25-002863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925002863/tm253091d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-002863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer